The Association of the British Pharmaceutical Industry (ABPI) has admitted Stallergenes Greer Plc as a full member.
Mike Thompson, chief executive of the ABPI, said:
"Stallergenes Greer is pioneering cutting-edge science in immunotherapies and gene therapies for patients globally. It's important that the ABPI provides a coherent and aligned voice for our industry, representing the views of UK-based global companies, small, medium and large. Having Stallergenes Greer as a full member increases our reach as the voice of Industry in the UK. We look forward to working together to ensure the UK remains at the forefront of helping patients prevent and overcome disease."
Stephen Mayhew, Global Head of Corporate Strategy at Stallergenes Greer Plc, said
"The UK is at the forefront of life science innovation in Europe hence the selection of London for the new global headquarters of Stallergenes Greer. We are looking forward to working with the ABPI and other leading pharmaceutical companies to ensure that patients in the UK continue to have access to the latest treatment options. While there are many questions about the future of the UK's relationship with Europe, it is the responsibility of the Industry, together with Health Authorities and Patient Groups to keep the interests of patients at the heart of the reform agenda."
About Stallergenes Greer plc
Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the US) and Stallergenes SAS (whose registered office is in France).
ABPI Press OfficeEmail: firstname.lastname@example.orgTelephone (24hrs): +44 (0) 20 7747 7147
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.